Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
Status:
Not yet recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S.
(N=746) to test the central hypothesis that IV iron in pregnant women with moderate-to-severe
IDA (Hb<10 g/dL and ferritin<30 ng/mL) at 24 - 28 weeks will be effective, safe and
cost-effective in reducing severe maternal morbidity-as measured by peripartum blood
transfusion-and will also improve offspring neurodevelopment.
Phase:
Phase 3
Details
Lead Sponsor:
Women and Infants Hospital of Rhode Island
Collaborators:
Hasbro Children's Hospital University of Michigan Washington University School of Medicine